Friday, 21 Sep 2018

You are here

Are ANA Tests Unreliable?

Pisetsky and colleagues have reported in the Annals of Rheumatic Disease that ANA tests done on established SLE patients may yield surprisingly disparate results.

While ANA negative lupus was a problem of old assays and the loss of ANA positivity may be seen with chronicity or age, most rheumatologists believe that ANA positivity is an absolute requirement for the diagnosis of systemic lupus erythematosus (SLE).

Researchers studied 103 patients with established SLE using three different immunofluorescence assays (IFA) for ANA determination. ANA determinations were also performed by an ELISA and bead-based multiplex assay.

With the IFA kits, ANA negativity was found in 4.9%–22.3% of serum samples. Moreover, the ELISA and multiplex assays found 11.7 to 13.6% seronegativity as well.

Patients with positive assays were more likely to have historic anti–double-stranded DNA positivity and low complement levels.

These findings raise numerous questions including whether these 5-22% of ANA seronegative lupus patients should be considered for clinical trials or managed differently.

Might these findings parallel that seen in rheumatoid arthritis with seronegative and seropositive populations?  While the overlap in treatment and outcomes is considerable, seropositivity (especially for ACPA) has the advantage of homogenizing the population under study.


The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

This is an important study done by recognized lupus experts. The question that I have is if all the SLE patient's who had sera tested were ANA positive at time of their original diagnosis. If so, then the question is at the time their sera was tested for this study, what treatment were they on and how active was their lupus. This was not included in this study. We have all had SLE patients who are well controlled on therapy and their ANA becomes negative. In my opinion, ANA negative patients either do not have SLE or are extremely well controlled on therapy and should not be included in lupus trials. Dr. Pisetsky does make a good point that all ANA assays are not equal in quality.
I very much appreciate Dr. West's comments on our study. In the study in ARD, we focused on kit variability. Ongoing studies are investigating possible determinants of any change in ANA status during the course of disease, recognizing potential differences among kits in ANA detection. We are very interested in those patients who become consistently ANA negative and, like Dr. West, wonder whether they still have SLE or should be in trials. The phenomenon of ANA negativity has not been well studied but is definitely worth attention as interest in remission in SLE grows.
What percentage of ANA negative patients on IFA may be due to prozone phenomenon (if dilution not done)? Also does significant proteinuria in nephritis patients alter the performance of the test and lead to negative results? Can these may be additional factors other than performance characteristics of the test kits per se.

More Like This

An Association between GCA and IBD ?

A population based analysis from Israel suggests that giant cell arteritis (GCA) patients may be at increased risk for  inflammatory bowel diseases (IBD) mainly target.

This research was based on sporadic reports in the medical literature (

Breast Implant Study: More Worries or Not?

The Annals of Surgery reports on an anlaysis of FDA-mandated postmarket studies, including nearly 100,000 breast implant pprocedures, that showed silicone implants to be associated with higher rates of  Sjögren's syndrome, scleroderma, rheumatoid arthritis, stillbirth, and melanoma.

New Classification of Idiopathic Inflammatory Myopathies

Using an observational cohort analysis of patients in the French myositis network, researchers have proposed a new classification of idiopathic inflammatory myopathies (IIM) with four subgroups: dermatomyositis, inclusion body myositis, immune-mediated necrotizing myopathy, and antisynthetase syndrome.

Rsearchers set out to define a classification system for IIM based on phenotypic, biological, and immunologic criteria. 

Depression Increases Risk of Systemic Lupus Erythematosus

Twenty-year data from the Nurses’ Health Study (NHS) suggests that depression is associated with a 2-fold increased frequency of systemic lupus erythematosus (SLE) - the question is why?

Interferon Blocker Disappoints in SLE

Yet another setback has occurred in the efforts to develop new medications for treating systemic lupus erythematosus (SLE), as anifrolumab failed to meet the primary endpoint in a phase III trial, according to AstraZeneca and MedImmune.